4.7 Article

Enhanced replication of swine influenza viruses in dexamethasone-treated juvenile and layer turkeys

Journal

VETERINARY MICROBIOLOGY
Volume 162, Issue 2-4, Pages 353-359

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.vetmic.2012.10.007

Keywords

Influenza virus; Turkeys; Dexamethasone

Funding

  1. United States Department of Agriculture
  2. CSREES AI-CAP project

Ask authors/readers for more resources

Frequent transmission of swine influenza viruses (SIVs) to turkeys has been reported since 1980s. Experimental studies also showed that SIVs can infect turkeys with varying replication and transmission efficiency depending on the strain. However, host factors involved in infection/replication efficiency remain unclear. To investigate whether the immune status of turkeys might play a role in the susceptibility of turkeys to SIVs, we studied the replication efficiency of two recent SIVs (human-like H1N2 and triple reassortant (TR) H3N2) in dexamethasone-treated turkeys. The viruses were inoculated intranasally in both dexamethasone-treated and untreated control juvenile and layer turkeys. Amount of virus shedding was monitored at 2, 4, and 7 days post inoculation (DPI). Additionally, passage of both viruses was attempted in dexamethasone-treated 4-week-old turkeys. In both juvenile and layer turkeys, we were able to detect human-like H1N2 Sly only from dexamethasone-treated turkeys and no virus was detected in untreated birds. The virus shedding of the TR H3N2 Sly was also consistently higher (approximate to 1 Log(10) EID50/ml) in dexamethasone-treated birds in both tracheal and cloacal swabs compared to untreated birds. Virus passage in dexamethasone-treated turkeys was successful up to the second passage and no virus was recovered from the third passage. These results show that potential immunosuppression due to dexamethasone treatment may enhance the transmission and adaptation of SIVs in turkeys through enhancement of virus replication, prolonged virus shedding, and possible decrease of infectious dose required to initiate infection. (C) 2012 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available